Gene therapy as a treatment for cancer is at a critical point in its evolution. Exciting new developments in gene targeting and vector technology, coupled with results from the first generation of preclinical and clinical studies have led to the design and testing of new therapeutic approaches. The Third Edition of Gene Therapy of Cancer provides crucial updates on the basic and applied sciences of gene therapy. It offers a comprehensive assessment of the field including the areas of suicide gene therapy, oncogene and suppressor gene targeting, immunotherapy, drug resistance gene therapy, and the genetic modification of stem cells. Researchers at all levels of development, from basic laboratory investigators to clinical practitioners, will find this book to be instructive. Cancer gene therapy, like cancer therapy in general, is evolving rapidly, testing new concepts, targets and pathways, evoking new technologies, and passing new regulatory hurdles. Its essence, however, has not changed: the hope and challenges of returning altered genes to normal, using targeted gene expression to alter the function of both tumor and microenvironment, and in some cases normal cells, and delivering functionally important genes to specific cell types to increase sensitivity to killing or to protect normal cells from cancer therapies. In some instances, gene therapy for cancer forms a continuum from gene repair through the use of molecularly modified cells; the use of viral and non-viral vector based gene delivery to both tumor and tumor microenvironment; the use of viral and gene based vaccines; and development of new gene-based therapeutics. The unique mechanistically chosen vector platforms are at the heart of this technology because they allow for direct and selective cell death and transient to sustained delivery of vaccine molecules or molecules that affect the microenvironment, vasculature, or the immune response. - Explains the underlying cancer biology necessary for understanding proposed therapeutic approaches- Presents in-depth description of targeting systems and treatment strategies- Covers the breadth of gene therapy approaches including immunotherapeutic, drug resistance,oncolytic viruses, as well as regulatory perspectives from both the NCI and FDA
List of Contributors
Jennifer E. Adair, Fred Hutchinson Cancer Research Center, Seattle, Washington
Jahangir Ahmed, Queen Mary University of London, London, United Kingdom
Ghassan Alusi, Queen Mary University of London, London, United Kingdom
Doron Amit, Hebrew University of Jerusalem, Jerusalem, Israel
Scott J. Antonia, University of South Florida, Tampa, Florida
Dominick L. Auci, University of Washington, Seattle, Washington
David A. August, Rutgers Cancer Institute of New Jersey and Rutgers Robert Wood Johnson Medical School, Rutgers, The State University of New Jersey, New Brunswick, New Jersey
Rutger K. Balvers, Erasmus Medical Center Rotterdam, Rotterdam, The Netherlands
Lajos Baranyi, Lentigen Corporation, Gaithersburg, Maryland
Brian C. Beard, Fred Hutchinson Cancer Research Center, Seattle, Washington
Sebastian Brennig, Research Group Reprogramming and Gene Therapy, REBIRTH Cluster-of-Excellence and Institute of Experimental Hematology, Hannover Medical School, Hannover, Germany
Elizabeth K. Broussard, University of Washington, Seattle, Washington
Paul D. Bryson, University of Southern California, Los Angeles, California
Andrew P. Byrnes, Center for Biologics Evaluation and Research, U.S. Food and Drug Administration, Rockville, Maryland
Denise L. Cecil, University of Washington, Seattle, Washington
Tim Chan, Intrexon Corporation, Germantown, Maryland
Charlie Comins, University of Surrey, Guildford, United Kingdom
Christiaan R. de Vries, Rutgers Cancer Institute of New Jersey and Rutgers Robert Wood Johnson Medical School, Rutgers, The State University of New Jersey, New Brunswick, New Jersey
Robert S. DiPaola, Rutgers Cancer Institute of New Jersey and Rutgers Robert Wood Johnson Medical School, Rutgers, The State University of New Jersey, New Brunswick, New Jersey
Clemens M.F. Dirven, Erasmus Medical Center Rotterdam, Rotterdam, The Netherlands
Mary L. Disis, University of Washington, Seattle, Washington
Boro Dropulic, Lentigen Corporation, Gaithersburg, Maryland
Heather Embree, Lentigen Corporation, Gaithersburg, Maryland
Michael W. Epperly, University of Pittsburgh Cancer Institute, Pittsburgh, Pennsylvania
Juan Fueyo, University of Texas M. D. Anderson Cancer Center, Houston, Texas
Toshiyoshi Fujiwara, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama, Japan
Hua Fung, Case Western Reserve University and University Hospital of Cleveland, Cleveland, Ohio
Emmanuel Gabriel, Rutgers Cancer Institute of New Jersey and Rutgers Robert Wood Johnson Medical School, Rutgers, The State University of New Jersey, New Brunswick, New Jersey
Vidya Ganapath, Rutgers, The State University of New Jersey, Piscataway, New Jersey
Stanton L. Gerson, Case Western Reserve University and University Hospitals Case Medical Center, Cleveland, Ohio
Steven Gill, Bristol University, AMBI LABS, Southmead Hospital, Bristol, United Kingdom
Michal Gilon, Hebrew University of Jerusalem, Jerusalem, Israel
Joe Goldufsky, Rush University Medical Center, Chicago, Illinois
Candelaria Gomez-Manzano, University of Texas M. D. Anderson Cancer Center, Houston, Texas
Jennifer Rubin Grandis, University of Pittsburgh and University of Pittsburgh Cancer Institute, Pittsburgh, Pennsylvania
Joel S. Greenberger, University of Pittsburgh Cancer Institute, Pittsburgh, Pennsylvania
John W. Greiner, National Institutes of Health, Bethesda, Maryland
Maneesh Gujrati, Case Western Reserve University, Cleveland, Ohio
James L. Gulley, National Institutes of Health, Bethesda, Maryland
Amin Hajitou, Phage Therapy Group, Imperial College London, London, United Kingdom
Kevin J. Harrington, Chester Beatty Laboratories, London, United Kingdom
Arash Hatefi, Rutgers, The State University of New Jersey, Piscataway, New Jersey
Loree C. Heller, Old Dominion University, Norfolk, Virginia
Richard Heller, Old Dominion University, Norfolk, Virginia
Akseli Hemminki, University of Helsinki, Helsinki, Finland
Otto Hemminki, University of Helsinki, Helsinki, Finland
Ronald B. Herberman, Intrexon Corporation, Germantown, Maryland
Daniel Herendeen, University of Washington, Seattle, Washington
Abraham Hochberg, Hebrew University of Jerusalem, Jerusalem, Israel
James W. Hodge, National Institutes of Health, Bethesda, Maryland
Gregory E. Holt, University of Washington, Seattle, Washington
Ying Huang, Center for Biologics Evaluation and Research, U.S. Food and Drug Administration, Rockville, Maryland
Insoo Hyun, Case Western Reserve University School of Medicine, Cleveland, Ohio
Hong Jiang, University of Texas M. D. Anderson Cancer Center, Houston, Texas
Shunsuke Kagawa, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama, Japan
Zahra Karjoo, Rutgers, The State University of New Jersey, Piscataway, New Jersey
Howard Kaufman, Rush University Medical Center, Chicago, Illinois
Chien-Chih Ke, National Yang Ming University, Taipei, Taiwan
Hans-Peter Kiem, Fred Hutchinson Cancer Research Center, Seattle, Washington
Jonathan Kimmelman, McGill University, Montreal, Quebec, Canada
Sarah R. Klein, University of Texas M. D. Anderson Cancer Center, Houston, Texas
Shinji Kuroda, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama, Japan
Seong Young Kwon, Chonnam National University Medical School, Jeonnam, Republic of Korea
Nico Lachmann, Research Group Reprogramming and Gene Therapy, REBIRTH Cluster-of-Excellence and Institute of Experimental Hematology, Hannover Medical School, Hannover, Germany
Hermann Lage, Institute of Pathology, Berlin, Germany
Martine L.M. Lamfers, Erasmus Medical Center Rotterdam, Rotterdam, The Netherlands
Edmund C. Lattime, Rutgers Cancer Institute of New Jersey and Rutgers...
Erscheint lt. Verlag | 28.8.2013 |
---|---|
Sprache | englisch |
Themenwelt | Informatik ► Weitere Themen ► Bioinformatik |
Medizin / Pharmazie ► Medizinische Fachgebiete ► Onkologie | |
Medizin / Pharmazie ► Medizinische Fachgebiete ► Pharmakologie / Pharmakotherapie | |
Studium ► 2. Studienabschnitt (Klinik) ► Humangenetik | |
Naturwissenschaften ► Biologie ► Genetik / Molekularbiologie | |
Technik | |
ISBN-10 | 0-12-394632-8 / 0123946328 |
ISBN-13 | 978-0-12-394632-4 / 9780123946324 |
Haben Sie eine Frage zum Produkt? |
Größe: 34,7 MB
Kopierschutz: Adobe-DRM
Adobe-DRM ist ein Kopierschutz, der das eBook vor Mißbrauch schützen soll. Dabei wird das eBook bereits beim Download auf Ihre persönliche Adobe-ID autorisiert. Lesen können Sie das eBook dann nur auf den Geräten, welche ebenfalls auf Ihre Adobe-ID registriert sind.
Details zum Adobe-DRM
Dateiformat: PDF (Portable Document Format)
Mit einem festen Seitenlayout eignet sich die PDF besonders für Fachbücher mit Spalten, Tabellen und Abbildungen. Eine PDF kann auf fast allen Geräten angezeigt werden, ist aber für kleine Displays (Smartphone, eReader) nur eingeschränkt geeignet.
Systemvoraussetzungen:
PC/Mac: Mit einem PC oder Mac können Sie dieses eBook lesen. Sie benötigen eine
eReader: Dieses eBook kann mit (fast) allen eBook-Readern gelesen werden. Mit dem amazon-Kindle ist es aber nicht kompatibel.
Smartphone/Tablet: Egal ob Apple oder Android, dieses eBook können Sie lesen. Sie benötigen eine
Geräteliste und zusätzliche Hinweise
Buying eBooks from abroad
For tax law reasons we can sell eBooks just within Germany and Switzerland. Regrettably we cannot fulfill eBook-orders from other countries.
Größe: 11,9 MB
Kopierschutz: Adobe-DRM
Adobe-DRM ist ein Kopierschutz, der das eBook vor Mißbrauch schützen soll. Dabei wird das eBook bereits beim Download auf Ihre persönliche Adobe-ID autorisiert. Lesen können Sie das eBook dann nur auf den Geräten, welche ebenfalls auf Ihre Adobe-ID registriert sind.
Details zum Adobe-DRM
Dateiformat: EPUB (Electronic Publication)
EPUB ist ein offener Standard für eBooks und eignet sich besonders zur Darstellung von Belletristik und Sachbüchern. Der Fließtext wird dynamisch an die Display- und Schriftgröße angepasst. Auch für mobile Lesegeräte ist EPUB daher gut geeignet.
Systemvoraussetzungen:
PC/Mac: Mit einem PC oder Mac können Sie dieses eBook lesen. Sie benötigen eine
eReader: Dieses eBook kann mit (fast) allen eBook-Readern gelesen werden. Mit dem amazon-Kindle ist es aber nicht kompatibel.
Smartphone/Tablet: Egal ob Apple oder Android, dieses eBook können Sie lesen. Sie benötigen eine
Geräteliste und zusätzliche Hinweise
Buying eBooks from abroad
For tax law reasons we can sell eBooks just within Germany and Switzerland. Regrettably we cannot fulfill eBook-orders from other countries.
aus dem Bereich